OncoAssure to Launch Next-Generation Prostate Cancer Test at AUA 2025

OncoAssure will debut its OncoAssure Prostate Test at the 2025 American Urological Association (AUA) Annual Meeting, taking place April 26–29in Las Vegas.

This next-generation prognostic tool is designed to support clinical decision-making for men diagnosed with localized prostate cancer. The test helps assess the risk of aggressive disease and disease recurrence and can be used at two key decision points in the prostate cancer pathway: post-biopsy and post-surgery.

Developed through the innovative OncoAssure Process, the test focuses on a concise panel of upstream “Master Driver” genes—key indicators of disease progression—offering clinicians a powerful tool for personalized patient management. (Learn more about the OncoAssure Process here)

OncoAssure Prostate is being commercialized in the U.S. in partnership with DiaCarta Inc., who will deliver the testing service from its ISO- and CAP/CLIA-certified laboratory in Pleasanton, California.

To learn more, visit OncoAssure and DiaCarta at Booth 223 during the AUA Annual Meeting.

The test can be ordered through DiaCarta.com